[18F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study

David L. Chan; Aimee Hayes; Ioannis Karfis; Alice Conner; Magdalena Mileva; Elizabeth Bernard; Shaunak Navalkissoor; Gopinath Gnanasekaran; Stephen J. Clarke; Paul J. Roach; Patrick Flamen; Martyn E. Caplin; Nick Pavlakis; Christos Toumpanakis; Dale L. Bailey

doi:10.2967/jnumed.124.269031

Research ArticleClinical Investigation

[¹⁸F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study

David L. Chan, Aimee Hayes, Ioannis Karfis, Alice Conner, Magdalena Mileva, Elizabeth Bernard, Shaunak Navalkissoor, Gopinath Gnanasekaran, Stephen J. Clarke, Paul J. Roach, Patrick Flamen, Martyn E. Caplin, Nick Pavlakis, Christos Toumpanakis and Dale L. Bailey

Journal of Nuclear Medicine May 2025, jnumed.124.269031; DOI: https://doi.org/10.2967/jnumed.124.269031

David L. Chan

1Medical Oncology Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia;

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Aimee Hayes

3Neuroendocrine Tumour Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ioannis Karfis

4Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Brussels, Belgium;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alice Conner

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Magdalena Mileva

4Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Brussels, Belgium;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elizabeth Bernard

5Nuclear Medicine Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shaunak Navalkissoor

3Neuroendocrine Tumour Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom;

6Nuclear Medicine Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gopinath Gnanasekaran

3Neuroendocrine Tumour Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom;

6Nuclear Medicine Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stephen J. Clarke

1Medical Oncology Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia;

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul J. Roach

5Nuclear Medicine Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Patrick Flamen

4Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Brussels, Belgium;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martyn E. Caplin

3Neuroendocrine Tumour Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nick Pavlakis

1Medical Oncology Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia;

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christos Toumpanakis

3Neuroendocrine Tumour Department, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dale L. Bailey

2Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;

5Nuclear Medicine Department, ENETS Centre of Excellence, Royal North Shore Hospital, Sydney, New South Wales, Australia; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Individuals

Non-Member Login

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 5

May 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following [18F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

[¹⁸F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study

Journal of Nuclear Medicine May 2025, jnumed.124.269031; DOI: 10.2967/jnumed.124.269031

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

[¹⁸F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study

Journal of Nuclear Medicine May 2025, jnumed.124.269031; DOI: 10.2967/jnumed.124.269031

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

prognostic biomarker
PET imaging
[18F]FDG
metabolic tumor volume

Main menu

User menu

Search

[¹⁸F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study

Individuals

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords